Evotec SE (LON: 0IRF)
London
· Delayed Price · Currency is GBP · Price in EUR
8.33
+0.21 (2.60%)
At close: Jan 30, 2025
Evotec SE Revenue
Evotec SE had revenue of 184.89M EUR in the quarter ending September 30, 2024, a decrease of -5.80%. This brings the company's revenue in the last twelve months to 777.05M, down -5.33% year-over-year. In the year 2023, Evotec SE had annual revenue of 781.43M with 3.99% growth.
Revenue (ttm)
777.05M EUR
Revenue Growth
-5.33%
P/S Ratio
n/a
Revenue / Employee
153.54K EUR
Employees
5,061
Market Cap
1.28B GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
Shell | 227.10B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
British American Tobacco p.l.c. | 26.18B |
BP p.l.c. | 144.69B |
Evotec SE News
- 11 days ago - Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases - Accesswire
- 4 weeks ago - Halozyme: Recent Approvals Alter My Appetite - Seeking Alpha
- 5 weeks ago - Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
- 7 weeks ago - Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk - Accesswire
- 2 months ago - Evotec Announces Change in Management Board - Accesswire
- 2 months ago - Comment on Withdrawn Non-Binding Offer - Accesswire
- 2 months ago - Halozyme withdraws $2.1 bln buyout offer for Evotec - Reuters
- 2 months ago - Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions - PRNewsWire